21 results about "Variable domain" patented technology

This disclosure relates to an immunoglobulin molecule having multiple variable domains that are each specific for a receptor, as well as heterodimeric molecules that include the multivariable domain immunoglobulin and a second heavy chain constant domain (HCCD2) of an antibody comprising a CH1 and a second Fc region (FC2), where FC1 and FC2 heterodimerize.

Herein is reported an antibody that binds to human A-beta protein wherein the antibody comprises a heavy chain variable domain (VH) and a light chain variable domain, the heavy chain variable domain and the light chain variable domain comprising a CDR selected from the group consisting of: (1) a CDR of SEQ ID NO: 85, 86, 87, 81, 82 and 83; or (2) a CDR of SEQ ID NO: 85, 89, 87, 81, 82, and 83; or (3) a CDR of SEQ ID NO: 85, 86, 87, 81, 82 and 91; or (4) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 91.

To provide bispecific antibodies that comprise a first variable domain that can bind an extracellular part of epidermal growth factor receptor (EGFR), and a second variable domain that can bind an extracellular part of MET Proto-Oncogene, Receptor Tyrosine Kinase (cMET).SOLUTION: An antibody may comprise a common light chain, and may be a human antibody. The antibody may be a full-length antibody. In some embodiments, the bispecific antibody is an IgG1 format antibody having an anti-EGFR, anti-cMET stoichiometry of 1:1. In some embodiments, the antibody has one variable domain that can bind EGFR and one variable domain that can bind cMET.SELECTED DRAWING: None

The present disclosure provides dual variable domain immunoglobulin (DVD-Ig) molecules that bind to human STEAP1 and human PSMA and their drug conjugates, and methods of using the same.

The present invention relates to Camelidae heavy chain only variable domain (VHH) molecules that bind to TfR, coupling compounds comprising such VHH molecules and their use for transporting molecules of pharmaceutical interest to cells and organs, for example under pathological conditions of CNS or PNS, including cancer.

The present invention relates to heavy chain-only variable domain (VHH) antibodies that specifically bind to transferrin receptor 1 (TfR1) and their use for transporting therapeutic or imaging agents intracellularly and across the blood-brain barrier.

The invention as disclosed herein relates to bispecific antibodies that comprises a first variable domain that can bind an extracellular part of epidermal growth factor receptor (EGFR) and a second variable domain that can bind an extracellular part of MET Proto-Oncogene, Receptor Tyrosine Kinase (cMET). The antibody may comprise a common light chain. It may be a human antibody. The antibody may be a full length antibody. In some embodiments the bispecific antibody is an IgG1 format antibody having an anti-EGFR, anti-cMET stoichiometry of 1:1. In some embodiment the antibody has one variable domain that can bind EGFR and one variable domain that can bind cMET.

Antibodies comprising unpaired variable domains, e.g., heavy chain variable (VH) domains, for binding antigen. Antibody comprising two immunoglobulin (Ig) chains, wherein a first Ig chain comprises a variable domain and a constant domain, and a second Ig chain comprises a constant domain, wherein the second Ig chain lacks a variable domain, leaving the variable domain of the first Ig chain unpaired. The antibody may comprise two Ig heavy chains and two Ig light chains, each heavy chain comprising a VH domain and a constant region comprising a CH1 domain, and each light chain comprising a CL domain, wherein one or both light chains lack a VL domain, thereby leaving one or both VH domains unpaired. Non-human animals (e.g., mice) engineered to produce antibodies having unpaired VH domains, involving deletion of sequence coding for light chain variable (VL) domains. Use of unpaired VH domains to generate antigen-binding molecules.

The present invention relates to bispecific antibodies comprising a first variable domain that can bind to an extracellular portion of the epidermal growth factor receptor (EGFR) and a second variable domain that can bind to an extracellular portion of the MET proto-oncogene, tyrosine kinase receptor (cMET). The antibody may comprise a common light chain. It may be a human antibody. The antibody may be a full-length antibody. In some embodiments, the bispecific antibody is an IgG1-format antibody having a 1:1 anti-cMET, anti-EGFR stoichiometry. In some embodiments, the antibody has a variable domain that can bind to EGFR and a variable domain that can bind to cMET.

This disclosure provides a dual variable domain immunoglobulin (DVD-Ig) molecule that binds to human STEAP1 and human PSMA, drug conjugates thereof, and methods of using them.

This disclosure provides polypeptides comprising antibody heavy chain variable domain (VH) variants, the VH variants comprising multiple antigen-binding regions and a framework comprising framework region 1, framework region 2, and framework region 3 (FWR3), wherein the VH variants have an amino acid sequence satisfying at least eight of the following criteria i)-x): i) the residue at Kabat position 19 is R, S, K, or T; ii) the residue at Kabat position 23 is T, V, A, or S; iii) the residue at Kabat position 24 is I, V, or S; iv) the residue at Kabat position 40 is selected from R, I, T, or K; v) the residue at Kabat position 43 is R, K, Q, E, or G; vi) the residue at Kabat position 44 is E, Q, A, D, or G; vii) the residue at Kabat position 45 is R, I, or L; viiii) the residue at Kabat position 76 is N or Q; ix) the residue at Kabat position 79 is Y, W, or F; and x) the residue at Kabat position 89 is V or I. The VH variant has improved basic stability and can be used as a backbone for affinity binding agents for in vitro applications, such as detecting, analyzing or separating analytes based on affinity interactions.

The present invention relates to heavy chain only variable domain (VHH) antibodies that specifically bind to transferrin receptor 1 (TfR1) and their use for transporting therapeutic or imaging agents into cells and across the blood brain barrier.

The present invention provides an antibody-drug conjugate (ADC), wherein the antibody is conjugated to the drug via cysteine-based site-specific conjugation, wherein the antibody comprises a first polypeptide comprising an immunoglobulin crystallizable fragment (Fc) region, at least one variable domain at the N-terminus of the Fc region, and an engineered IgG hinge region between the Fc region and the at least one variable domain, wherein the engineered IgG hinge region is heterologous to and / or mutated with respect to the Fc region to provide a predetermined number of cysteine ​​residues.

The present invention relates to an antibody comprising a heavy chain variable domain (VH domain) and a light chain variable domain (VK domain), characterized in that a) the amino acid sequence of the VH domain is defined in SEQ ID NO: 3, the amino acid sequence of the VK domain is defined in SEQ ID NO: 7; ob) the amino acid sequence of the VH domain is defined in SEQ ID NO: 4, and the amino acid sequence of the VK domain is defined in SEQ ID NO: 7; oc) the amino acid sequence of the VH domain is defined in SEQ ID NO: 5, and the amino acid sequence of the VK domain is defined in SEQ ID NO: 8; od) the amino acid sequence of the VH domain is defined in SEQ ID NO: 5, and the amino acid sequence of the VK domain is defined in SEQ ID NO: 7; and where the antibody binds to the amyloid peptides AßpE3-42 and Aß-42 and does not bind to the amyloid peptide Aß1-42.

The invention as disclosed herein relates to bispecific antibodies that comprises a first variable domain that can bind an extracellular part of epidermal growth factor receptor (EGFR) and a second variable domain that can bind an extracellular part of MET Proto-Oncogene, Receptor Tyrosine Kinase (cMET). The antibody may comprise a common light chain. It may be a human antibody. The antibody may be a full-length antibody. In some aspects, the bispecific antibody is an IgG1 format antibody having an anti-EGFR, anti-cMET stoichiometry of 1:1. In some aspects, the antibody has one variable domain that can bind EGFR and one variable domain that can bind cMET.

The present disclosure relates to dual variable domain immunoglobulin double-stranded RNA conjugates, which are advantageous for inhibiting target gene expression, and compositions suitable for therapeutic use.Dual variable domain immunoglobulins comprise a first variable domain that binds to a binding target and a second variable domain that comprises a reactive residue, and a linker is covalently conjugated to the reactive residue.dsRNA is linked to the linker and has the ability to inhibit target gene expression by RNA interference.The present disclosure also provides pharmaceutical compositions comprising these conjugates, and methods for inhibiting target gene expression by administering these conjugates, for example, to treat various disease conditions. TIFF2022538404000087.tif64156

The present invention relates to heavy chain-only variable domain (VHH) antibodies that specifically bind to transferrin receptor 1 (TfR1) and their use to transport therapeutic or imaging agents intracellularly and across the blood-brain barrier.

The present invention relates to multi-domain binding molecules. The molecules comprise i) a peptide-major histocompatibility complex (pMHC) binding domain comprising a first variable region linked to a constant region (VC1) and a second variable region linked to a constant region (VC2), wherein VC1 and VC2 dimerise to form the pMHC binding domain; ii) an immune cell engaging domain comprising an antibody light chain variable domain (TCE-VL) linked to an antibody heavy chain variable domain (TCE-VH); and iii) a half-life extending domain comprising a first portion of an IgG Fc region (FC1) and a second portion of an IgG1 Fc region (FC2); wherein the multi-domain binding molecule comprises: a first polypeptide chain in which the immune cell engaging domain is linked to the N terminus of VC1; a second polypeptide chain in which VC2 is linked via its C terminus to the N terminus of FC1; and a third polypeptide chain comprising FC2; and wherein the pMHC binding domain and the immune cell engaging domain are capable of binding to a pMHC complex and a T cell respectively. The binding molecules can be used to treat diseases such as cancer, autoimmune diseases and infectious diseases.

The present invention relates to a novel human variable domain scaffold and a single domain antibody library based on same. The scaffold according to the present invention is monomeric and stable, and maintains appropriate folding, and is sufficiently flexible to withstand various CDR loop shapes, thereby being able to accommodate various CDR sequences and shapes, and thus is very suitable for use as a scaffold for an antibody library.